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Abstract 
DLX5 belongs to the six-member family of DLX 
genes characterized by a homeobox related to that 
found in the insect Distal-less (Dll) gene. The six 
DLX genes are organized as three bigenic pairs 
with a tail-to-tail orientation (Zerucha et al., 2000) 
and located on chromosomes where HOX clusters 
are also found (DLX5/DLX6; 7q21.3, syntenic to 
the HOXA cluster), (DLX1/DLX2; 2q32, syntenic 
to the HOXD cluster; Simeone et al., 1994) and 
(DLX3/DLX4; 17q21.33, syntenic to the HOXB 
cluster). During embryonic development DLX 
genes are involved in the control of appendage and 
craniofacial morphogenesis and in the 
differentiation of reproductive organs; in the adult 
they play a role in bone homeostasis and in the 
maintenance of tissue integrity. 
Identity 
Other names: SHFM1D 
HGNC (Hugo): DLX5 
Location: 7q21.3 
Local order: -DLX6-DLX5-ACN9- 
DNA/RNA 
Description 
The DLX5 gene is composed of 3 exons spanning a 
genomic region of 4442 bp. 
Genomic features 
Mutations: Breakpoint analyses of genomic 
deletions and chromosomal rearrangements in the 
congenital split-hand/split-foot malformation 
(SHFM type 1D, OMIM #220600), have shown 
that positional effect and disrupted regulatory 
elements controlling DLX5/DLX6 activity are 
involved in the pathogenesis of this developmental 
disorder (see further "dysmorphologies").  
In-depth sequencing of the candidate regions has 
shown that the expression of DLX6 depends upon 
the activity of conserved regulatory elements shared 
with DLX5, and located both within the 
DLX5/DLX6 intergenic territory and outside of the 
locus (Lango Allen et al., 2014).  
Furthermore these enhancers have been identified 
in all examined species - including in mouse where 
transgenic analyses have allowed the functional 
characterization of their tissue-specificity. 
 
Local order of DLX5 and flanking genes DLX6 and ACN9 is shown, with centromere at left and telomere (qter) at right. Arrows 
indicate transcriptional orientation of individual genes. DLX6 gene range: 96635290 - 96640352; DLX5 gene range: 96649702 - 
96654143; ACN9 gene range: 96745905 - 96811075 (Hillier et al., 2003). 
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Exon 1: 1 - 563; exon 2: 2463 - 2647; exon 3: 3767 - 4442. 
 
 
Moreover, recent analyses of genomic integrity in 
SHFM1D probands have unravelled two new 
intragenic, non-synonymous mutations within the 
open reading frame of DLX5. 
Imprinting: The status of parental imprinting of 
the DLX5/DLX6 locus has recently gained strong 
interest as these genes have been considered to be 
putative methylation targets of the methyl-CpG 
binding protein-2 (MECP2), and thus might be 
indirectly involved in the aetiology of the Rett 
syndrome, a severe X-linked neurodevelopmental 
disorder afflicting girls with MECP2 mutation (see 
further "Rett syndrome"). 
Transcription 
The DLX5 coding sequence consists of 870 bp 
from the start of the first codon to the stop codon 





The DLX5 protein consists of 289 amino acids with 
a calculated molecular weight of 31,5 kDa.  
The protein contains two motifs, one dubbed 
homeobox protein distal-less-like N terminal and a 




Transcription factor important in the control of 
bone formation in embryonic development (Hassan 
et al., 2004). Transcription from DLX5 yields three 
splice variants, which range from 1062 b to 1688 b 
(major isoform) due to alternative splicing sites 
throughout the precursor transcript. The shortest 
(Dlx5-002) is not processed. The other two share 
exon 1 which encodes an N-terminal DLL domain, 
and exon 2 which encodes a part of the  
homeodomain. The shorter transcript (DLX5-003) 
encodes a predicted 191 AA-long, 20.9 kDa 
isoform with both N-terminal DLL domain and a 
homeodomain.  
It should be observed that in vitro 35S-primed 
expression from full-length murine Dlx5 yields 
only one isoform at 32 kDa (Zhang et al., 1997). 
The latter study provided evidence for an 
incompatibility between Dlx5 DNA binding to its 
target homeodomain-responsive element 
(TAATTA) and heterodimerization with its partner 
Msx factor.  
It further showed that both events were mutually 
antagonistic, suggesting a regulatory role during 
Dlx/Msx-controlled morphogenetic processes such 
as branchial arch and limb formation. During bone 
formation, Dlx5 (pI 9.3) transactivation activity is 
enhanced through serine phosphorylation in the 
nucleus by p38 MAP-kinase upon BMP2 signaling 
(Ulsamer et al., 2008).  
Dlx5 has further been shown to be subjected to 
threonine phosphorylation by PKA during BMP2-
induced osteoblast differentiation, which increases 
Dlx5 nuclear levels by improving its stability (Han 
et al., 2011). 
Homology 
None reported to date. 
Mutations 
Germinal 
A novel DLX5 mutation (c.A533C: p.Q178P) was 
identified in a family with autosomal recessive split 
hand and foot malformation (Shamseldin et al., 
2012).  
Recently, a second rare familial case of SHFM1 has 
been demonstrated to result, with highest 
probability, from intragenic missense mutations of 
a critical glutamine residue in the third helix of the 
DLX5 homeodomain - Q186H (Wang et al., 2014). 
The encoded mutant DLX5 has been demonstrated 
to fail at transactivating a bona fide MYC target.  
 
 
DLL_N: homeobox protein distal-less-like N terminal; Homeodomain: homeobox DNA binding domain. 
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NCBI/COBALT alignment of DLX homeoproteins. Note the disposition according to the DLX 1/4/6 versus DLX 2/3/5 clades. 
Indicated by a yellow box is the ultraconserved glutamine featured by most homeoproteins at position 50 of the homeodomain. 
 
Such an observation is not unexpected as this 
mutation affects Q50, the most conserved residue of 
all homeoproteins (see diagram above), which 
numerous biochemical studies have demonstrated 
to be responsible for the specificity of the DNA 
recognition at the TAATT homeo-element (for 
review, Galliot et al., 1999). 
Somatic 
A DLX5 mutation (c.C119G: p.S40C) was 
observed in an ovarian carcinoma (Cancer Genome 
Atlas Research Network, 2011). 
Overexpression of DLX5 has been reported in 
several types of human malignancy including lung 
cancer (Kato et al., 2008; Xu and Testa, 2009), T-
cell lymphoma (Tan et al., 2008), and ovarian 




The DLX5 gene was reported to be overexpressed 
in the great majority of human non-small cell lung 
cancers examined by Kato et al., 2008. 
Furthermore, immunohistochemical studies 
revealed that positive immunostaining for DLX5 
correlated with tumor size and poorer prognosis. 
A DLX5 transcript isoform has been shown to be 
strongly overexpressed in a large panel of primary 
lung cancer samples, providing a reliable prognosis 
marker (Kato et al., 2008). In this study, the 
detected isoform (1.8 kb on Northern blot using a 
probe spanning exon 3 and 3'UTR) was claimed to 
be found only in the placenta, among 23 normal 
adult tissues. It should be observed that other 
studies have reported numerous expression sites in 
adult human, including bone (osteoblasts and 
marrow), ear, tooth, fat and brain. With regards to 
function, down-regulation of DLX5 through RNA 
interference compromised the growth or survival of 
two lung cancer cell lines, suggesting that 
controling DLX5 expression levels might be 
clinically relevant (Kato et al., 2008). 
Lymphoma 
Note 
DLX5 was found to be highly expressed in 3 of 7 
(42%) patient-derived T-cell lymphomas compared 
with that observed in nonmalignant lymph node 
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samples (Tan et al., 2008). In addition, these 
investigators found repeated upregulation of Dlx5 
in T-cell lymphomas from transgenic mice in which 
the Lck promoter was used to drive expression of a 
constitutively active form of Akt2 in the thymus. 
Dlx5 was overexpressed due to a novel 
chromosome inversion that placed the T-cell 




Both DLX5 and DLX6 were found to be 
upregulated during metastasis formation after 
intravenous injection of MDA-MB-231 breast 
cancer cells. The in vitro treatment of MDA-MB-
231 cells with endothelin 1, a peptide associated 
with breast cancer invasive phenotype, resulted in a 
switch from DLX2 to DLX5 expression. Mutually 
exclusive expression of DLX2 and DLX5 was 
found in both MDA-MB-231 cells and human 
breast cancer specimens. This evidence suggested 
that DLX genes are involved in human breast 
cancer progression, and that expression of DLX2 
and DLX5 genes might serve as prognostic markers 
(Morini et al., 2010). 
Astrocytoma 
Note 
Transcriptional profiling in search for prognosis 
markers has identified DLX5 as an upregulated 




DLX5 mRNA is abundantly expressed in many 
cancer cell lines derived from malignant tissues of 
breast, brain, lung, skin, and ovarian cancer 
patients, whereas expression of DLX5 was low or 
undetectable in tumor cells from patients with 
leukemia or with colorectal, prostate, and kidney 
cancers (Tan et al., 2010). 
Dysmorphologies 
Note 
Split hand-foot malformation (SHFM) type 1 with 
sensory-neural hearing loss (SHFM1D; 
MIM:220600). This malformative syndrome affects 
hands and feet alike, resulting in moderate to severe 
median ray deficiency with syndactily. Among the 
described six non-syndromic SHFM loci, one spans 
the DLX5/DLX6 bigenic cluster (Scherer et al., 
1994; Crackower et al., 1996). However, numerous 
reported mutations spare DLX5 or DLX6 open 
reading frames, suggesting it may rather be their 
common regulatory elements which is impacted 
(Robledo et al., 2002; Lo Iacono et al., 2008). 
However recently, one rare familial case of SHFM1 
has been demonstrated to result, with highest 
probability, from an intragenic missense mutation 
of the DLX5 homeodomain (Q178P; Shamseldin et 
al., 2012). In the latter case, a causal link between 
defective DLX5/DLX6 expression and the 
pathogenic mechanism impairing limb development 
remains to be elucidated (Lango Allen et al., 2014). 
On a further note, SHFM cases have often been 
reported to include hearing loss, a trait consistent 
with a developmental role demonstrated for 
Dlx5/Dlx6 during ear formation in mouse 
embryogenesis (Acampora et al., 1999; Merlo et al., 
2002; Robledo and Lufkin, 2006; Chatterjee et al., 
2010; Frenz et al., 2010). Moreover, both genes are 
major targets of two regulator genes whose 
deficiencies are responsible for a related pathogenic 
condition, the auriculo-condylar syndrome (ACS, 
Rieder et al., 2012; Brown et al., 2010). 
Anorectal malformation associated with SHFM has 
been reported in a family with a missense mutation 
in the P63 gene, a known direct upstream regulator 
of DLX5/DLX6 during morphogenesis (Su et al., 
2013). Whether DLX5/DLX6 expression is 
dysregulated in this condition, and whether this trait 
can be functionaly associated with the phenotype, 
remains to be elucidated. 
Rett syndrome 
Note 
DLX5 and DLX6 (OMIM 600028) have been 
controversial candidates for neurodevelopmental 
defects progressively afflicting young girls 
suffering of Rett syndrome (OMIM 312750). This 
late onset disorder features fatal motor 
abnormalities, seizures, autism and mental 
retardation. While the genomic sequence of the 
DLX5/DXL6 locus remains unaffected in all 
reported cases, it is a direct target of the 
transcriptional regulator methyl-CpG-binding 
protein 2 (MeCP2), which has been strongly 
associated to this syndrome by linkage analysis 
(Horike et al., 2005). While still debated (Horike et 
al., 2005; Schüle et al., 2007; LaSalle, 2007; 
Miyano et al., 2008), initial MeCP2 deficiency is 
considered as causing defective neurogenesis 
through dysregulated expression of DLX5/DLX6, 
due to altered chromatin state at this target locus 
(Horike et al., 2005; Lilja et al., 2013). Mouse 
mutagenesis has substantiated this hypothesis by 
pinpointing GABA (γ-aminobutyric acid)-releasing 
neurons as a major cellular target expressing Dlx5 
and Dlx6, whose deficiency impairs neurogenesis 
in MeCP2 null mutant (Chao et al., 2010). 
Osteoporosis 
Note 
Mouse mutational studies have demonstrated a role 
for Dlx5 and Dlx6 as a major determinant of 
chondrogenesis and chondrocyte hypertrophy in the 
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endochondral skeleton, throughout embryogenesis 
and adulthood (Samee et al., 2007; Samee et al., 
2008; Samee et al., 2009). These observations pave 
the way for a better understanding of human 
osteoporosis, in particular in patients with 
dysfunctional regulation of bone-remodeling 
hormonal levels (Prall et al., 2013). 
Reproductive tract 
Note 
Dlx5 and Dlx6 are involved in the development and 
function of the reproductive tract. The dual mouse 
mutant for Dlx5 and Dlx6 displays abnormal 
urethra formation (Suzuki et al., 2007), reduced 
testicular steroidogenesis with feminization 
(Nishida et al., 2008), and early ovarian follicular 
depletion (Bouhali et al., 2011). A human mutation 
in a genomic region including DLX5 and DLX6 has 
been associated to a case of familial premature 
ovarian failure (Caburet et al., 2012). 
Teratology 
Note 
With regards to pharmacologically-induced 
teratogenesis, dysregulation of DLX5/DLX6 gene 
expression has been demonstrated to be a major 
step during craniofacial embryopathy induced by 
two compounds:  
i) retinoic acid, a vitamin A derivative found in the 
RoAccutane ® drug, which indirectly prevents the 
induction of DLX5/DLX6 in human (Lammer et 
al., 1985; Coberly et al., 1996) and in all animal 
models investigated (Vieux-Rochas et al., 2007), 
which share a wide range of jaw and ear 
malformations;  
ii) the food contaminant ochratoxin A, a fungal 
toxin demonstrated to prevent Dlx5 activation in 
exposed mouse embryos, which later develop 
craniofacial malformations (Wei and Sulik, 1993; 
Napoletano et al., 2010). Although a causal link 
between Dlx5, Dlx6 and the toxin remains to be 
functionally demonstrated, this observation may 
account for teratogenesis observed in human 
embryos maternally exposed to the toxin (Hope and 
Hope, 2012; Thrasher et al., 2012). 
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